[Clinical and therapeutic approach to anxiety-depression syndromes. Effectiveness of bromazepam (author's transl)].
In anxiety-depression syndromes intricacy of the symptoms is such that the relative importance of the two components must be assessed for adequate treatment with anxiolytic and/or antidepressant drugs. The anxiolytic activity of bromazepam was evaluated in 30 patients with anxiety-depression syndrome. A tricyclic antidepressant was added in cases with marked disorders in mood. Results were assessed by means of the Hamilton and Pull-Guelfi scales and Beaumont's self-evaluation scores. Fourteen patients were treated with bromazepam alone in doses adjusted to the therapeutic response, and 16 patients received both bromazepam showed rapid and consistent anxiolytic activity, except in 4 cases which required adjunction of an antidepressant. The drug was well tolerated, provided individual susceptibilities were taken into consideration.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D001960:Bromazepam / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male
D014151:Anti-Anxiety Agents; D001960:Bromazepam
Approche clinique et thérapeutique des syndromes anxio-dépressifs. Intérêt du bromazépam.